Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 17/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.65 |
| ▸ | MELK | Q14680 | 1/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24717341 | 0.93 | BCL6 (0.66) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267551 | 0.92 | BCL6 (0.65) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL20284729 | 0.92 | BCL6 (0.65) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267051 | 0.92 | BCL6 (0.66) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267063 | 0.91 | BCL6 (0.65) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL20284080 | 0.91 | BCL6 (0.78) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267137 | 0.90 | BCL6 (0.71) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267136 | 0.90 | BCL6 (0.71) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267152 | 0.90 | BCL6 (0.69) | BCL6NCOR2MELKCHRM4BCL6B | |
| SCHEMBL23267135 | 0.90 | BCL6 (0.62) | BCL6NCOR2MELKCHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |